• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Buprenorphine for Suicidality? Maybe

Buprenorphine for Suicidality? Maybe

July 1, 2016
Bret A. Moore, PsyD, ABPP
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
bret-a-moore-psyd-abppBret A. Moore, PsyD, ABPP Board-Certified Clinical Psychologist, San Antonio, TX Dr. Moore has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Subject: (Yovell Y et al, Am J Psychiatry 2016;173:491–498)

Short Description: When patients become severely suicidal, we have few good treatment options. These include close monitoring (often in a locked unit), intensive psychotherapy, antidepressants (which, while effective, take weeks to work), a variety of medications to treat symptoms such as agitation and insomnia, and more recently, the experimental treatment ketamine (which requires repeated infusions under medical supervision). In addition, lithium reduces suicidality in bipolar disorder, and clozapine does so in schizophrenia—but both are long-term treatments.

Recognizing the need for more options, Israeli researchers studied the use of very low doses of buprenorphine in suicidal patients. Patients with suicidal ideation were recruited from four medical centers. The participants were severely suicidal, with an average score of 19.7 on the Beck Scale for Suicidal Ideation; 64% of them had made at least one suicide attempt. They were randomly assigned to either buprenorphine (n = 40) or placebo (n = 22). Buprenorphine was started at 0.1 mg once or twice a day and gradually titrated up to a max dose of 0.8 mg/day (average dose was 0.44 mg/day). No changes to the regular psychiatric treatment were made. Most of the patients’ from both groups were on medication, including over 70% who were taking antidepressants. The primary outcome measure was change from baseline on the Beck scale, which was assessed weekly for 4 weeks.

The buprenorphine seemed to work. After 2 weeks, suicide severity dropped by an average of 4.3 points more in the buprenorphine group than the placebo group, and after 4 weeks, the difference was 7.1 points; both values were statistically significant. Adverse events occurred in 77.2% of the buprenorphine patients, and in 54.8% of the placebo patients. The most common buprenorphine-related side effects were fatigue (49.1%), nausea (36.8%), and constipation (26.3%). After 4 weeks, the medication was stopped without a taper, and no patients reported any withdrawal symptoms over the ensuing week, nor was there any exacerbation in suicidality.

TCPR’s Take: This was a small study and of short duration, but the results were encouraging. A brief course of ultra-low-dose buprenorphine may be worth trying in your patients with severe suicidal ideation. Keeping the dose low and limiting the duration to around 4 weeks are likely crucial for preventing opioid addiction in these patients.
General Psychiatry
KEYWORDS addiction depressive_disorder research-update
Bret a moore psyd abpp
Bret A. Moore, PsyD, ABPP

Extended-Release Guanfacine Improves ADHD Symptoms in Autism

More from this author
www.thecarlatreport.com
Issue Date: July 1, 2016
SUBSCRIBE NOW
Table Of Contents
Metoclopramide Helps Clozapine-Related Drooling
N-acetylcysteine Shows Promise for Skin-Picking Disorder
Buprenorphine for Suicidality? Maybe
Citalopram Safety Warning Has Serious Consequences for VA Patients
Take The CME Test For Medication in Pregnancy, TCPR, July/August 2016
How to Evaluate and Treat Mood Disorders in Pregnancy
What’s New with the FDA Labeling for Pregnancy and Lactation?
Assessing Illness and Medication Treatment in the Perinatal Period
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.